Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer
- 13 October 2017
- journal article
- case report
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 17 (12), 1093-1098
- https://doi.org/10.1080/14737140.2017.1390432
Abstract
Introduction: In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refractory differentiated thyroid carcinoma (DTC). Unfortunately, in some cases the efficacy of TKIs is limited by the onset of drug resistance after the initial response. Areas covered: We report the case of a patient with a RAI refractory advanced DTC, treated with lenvatinib after surgery, multiple RAI administrations, traditional chemotherapy, and sorafenib. During treatment with lenvatinib, a noticeable response was detected by sequential computed tomography scans but, after 27 months, tumor progression became evident and led to lenvatinib interruption. In absence of any active treatment, a further disease progression was documented, and lenvatinib was re-administered obtaining a new objective response. Starting from this case report, we review available reports about the rechallenge with TKIs in solid tumors, discussing the possible mechanisms underlying the efficacy of this approach. Expert commentary: Rechallenge with TKIs in solid tumors could be a therapeutic option in subjects with advanced and metastatic DTC who experience a progressive disease after initial response to lenvatinib.Keywords
Funding Information
- Eisai (no specific number)
This publication has 31 references indexed in Scilit:
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Proceedings of the National Academy of Sciences of the United States of America, 2012
- High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinomaJournal of Translational Medicine, 2011
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene ExpressionPLOS ONE, 2011
- Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two CasesUrologia Internationalis, 2010
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft StudyMolecular Cancer Therapeutics, 2010
- Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibClinical Therapeutics, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Remarkable Effect of Gefitinib Retreatment in a Patient with Nonsmall Cell Lung Cancer Who Had a Complete Response to Initial GefitinibThe American Journal of the Medical Sciences, 2007
- Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancerBMC Cancer, 2007
- Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistanceAnnals of Oncology, 2004